vCCI Inhibitors
Viral CC chemokine inhibitor (vCCI) is a protein encoded by certain poxviruses, which has been shown to play a crucial role in the modulation of the host immune response. vCCI achieves this by binding to CC chemokines, a type of signaling protein that attracts immune cells to the site of infection. By sequestering these chemokines, vCCI effectively blunts the chemotactic gradient necessary for immune cell recruitment, allowing the virus to evade an immediate and robust attack by the host's immune system. Understanding the expression and function of vCCI is paramount for researchers studying viral pathogenesis and host-virus interactions. The protein's unique ability to bind a broad range of CC chemokines with high affinity makes it an intriguing target for studying viral immune evasion mechanisms. Since vCCI operates by interfering with immune cell signaling, the modulation of its expression is a key research focus, as altering its levels could influence the course of viral infection.
In the quest to understand how to modulate the expression of vCCI, identifying chemicals that could potentially inhibit its expression is an area of active investigation. These chemicals typically exert their influence by interfering with various stages of the viral life cycle or by hindering the cellular pathways that are co-opted by viruses for replication and protein production. For instance, nucleotide analogs that target viral DNA polymerase can prevent the synthesis of viral DNA, thereby indirectly reducing the expression of vCCI. Other compounds, such as those interfering with the replication of viral RNA or inhibiting key viral enzymes, can lead to a downregulation of vCCI expression due to a decrease in the overall production of viral components. Additionally, some chemicals may inhibit the integration of viral DNA into the host genome or the processing of viral proteins, further contributing to the reduction in vCCI expression. It's important to note that the study of such chemicals and their potential to inhibit vCCI expression serves to better understand the biological functions and interactions of this viral protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acyclovir | 59277-89-3 | sc-202906 sc-202906A | 50 mg 500 mg | $150.00 $940.00 | 2 | |
Acyclovir mimics nucleoside analogs that, upon incorporation into viral DNA by viral DNA polymerase, result in chain termination. This action could downregulate vCCI expression by preventing the synthesis of viral DNA where the vCCI gene resides. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin causes lethal mutagenesis in RNA viruses and inhibits inosine monophosphate dehydrogenase, which could decrease vCCI expression by curtailing the replication of viral RNA necessary for its production. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $61.00 | 2 | |
3′-Azido-3′-deoxythymidine is a thymidine analog that interferes with reverse transcriptase activity, potentially reducing vCCI expression in retroviruses by blocking the reverse transcription of viral RNA into DNA. | ||||||
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $146.00 | 1 | |
Sofosbuvir inhibits the NS5B polymerase in hepatitis C virus, which could theoretically inhibit vCCI expression by thwarting the replication of viral RNA genomes. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide's active metabolite inhibits pyrimidine synthesis, which could lead to a decrease in vCCI expression by limiting the availability of nucleotides required for viral replication. | ||||||
Cidofovir | 113852-37-2 | sc-482141 | 50 mg | $135.00 | ||
Cidofovir acts as a competitive inhibitor of viral DNA polymerases, potentially reducing vCCI expression by disrupting the elongation phase of viral DNA replication. | ||||||
1-Adamantylamine | 768-94-5 | sc-251475 sc-251475A | 1 g 25 g | $39.00 $147.00 | ||
1-Adamantylamine disrupts the proton channel activity of the M2 protein in influenza viruses, which could decrease vCCI expression by preventing the virus from releasing its genetic material into host cells. | ||||||
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $157.00 $646.00 | 11 | |
Tenofovir is an adenosine analog that inhibits reverse transcriptase enzymes, potentially reducing vCCI expression by preventing viral DNA synthesis in the retroviral replication cycle. | ||||||
Raltegravir | 518048-05-0 | sc-364600 sc-364600A sc-364600B sc-364600C sc-364600D | 5 mg 50 mg 100 mg 500 mg 1 g | $100.00 $821.00 $1229.00 $2861.00 $4085.00 | 21 | |
Raltegravir targets the integrase enzyme, which could reduce vCCI expression by inhibiting the integration of viral cDNA into the host cell's genome, a critical step for viral gene expression. | ||||||
Atazanavir | 198904-31-3 | sc-207305 | 5 mg | $292.00 | 7 | |
As a protease inhibitor, Atazanavir could decrease vCCI expression by inhibiting the cleavage of viral polyprotein precursors into mature proteins, which is essential for producing infectious viral particles. | ||||||